Novasep has signed a letter of intent to supply the API for Pfizer’s Paxlovid, an oral protease inhibitor against COVID-19 that has shown a positive impact in clinical trials on hospitalisation among at-risk patients Technical transfer, on-site development and equipment installation activities have begun already at the Mourenx facility in France, which is expected to be incorporated into the supply chain by Q3.

French-based CDMO Novasep has announced two sales. Henagen, its Belgium-based viral vectors operation, has been sold to Thermo Fisher Scientific for about €725 million, while, in a much smaller deal, it also intends to sell its chromatography equipment division to Sartorius Stedim Biotech.